Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?

Sali, Shahnaz; Sharafi, Heidar; Alavian, Seyede Hoda; Alavian, Seyed Moayed; Etesam, Faranak; Salimi, Shima; Merza, Muayad Aghali; Keshvari, Maryam

doi:10.1016/j.diagmicrobio.2015.02.005

Cited by 10 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In despite of their distinct pathogenic processes of infections, both CHB and CHC can lead to cirrhosis, hepatic failure, and hepatocellular carcinoma (Arzumanyan et al, 2013 ). HBV serologic markers such as hepatitis B surface antigen (HBsAg), hepatitis B envelope antigen (HBeAg), hepatitis B core antigen (HBcAg), and anti-HCV antibody have been used in diagnosing and monitoring the progress of viral liver disease, some even has been introduced to evaluate treatment response to interferon (Sali et al, 2015 ). However, the dynamics of viral proteins expression and productions of the antibodies may vary, for instance, negative HBsAg cannot exclude HBV infection (He et al, 2003 ).…”

Section: Introductionmentioning

confidence: 99%

Comparative Analysis for Glycopatterns and Complex-Type N-Glycans of Glycoprotein in Sera from Chronic Hepatitis B- and C-Infected Patients

Qin

Guo

et al. 2017

Front. Physiol.

View full text Add to dashboard Cite

Background: Chronic infection with HBV (CHB) or HCV (CHC) is the most common chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma in humans, their infections have distinct pathogenic processes, however, little is known about the difference of glycoprotein glycopatterns in serum between hepatitis B virus (HBV)- and hepatitis C virus (HCV)-infected patients.Methods: A method combining the lectin microarrays, letin-mediated affinity capture glycoproteins, and MALDI-TOF/TOF-MS was employed to analyze serum protein glycopatterns and identify the glycan structures from patients with CHB (n = 54) or CHC(n = 47), and healthy volunteers (HV, n = 35). Lectin blotting was further utilized to validate and assess the expression levels of their serum glycopatterns. Finally, the differences of the glycoprotein glycopatterns were systematically compared between CHB and CHC patients.Conclusions: As a result, there were 11 lectins (e.g., HHL, GSL-II, and EEL) exhibited significantly increased expression levels, and three lectins (LCA, VVA, and ACA) exhibited significantly decreased expression levels of serum protein glycopatterns only in the CHB patients. However, DBA exhibited significantly decreased expression levels, and two lectins (WGA and SNA) exhibited significantly increased expression levels of serum glycopatterns only in the CHC patients. Furthermore, LEL and MAL-I showed a coincidentally increasing trend in both CHC and CHB patients compared with the HV. The individual analysis demonstrated that eight lectins (MPL, GSL-I, PTL-II, UEA-I, WGA, LEL, VVA, and MAL-I) exhibited a high degree of consistency with the pooled serum samples of HV, CHB, and CHC patients. Besides, a complex-type N-glycans binder PHA-E+L exhibited significantly decreased NFIs in the CHB compared with HV and CHC subjects (p < 0.01). The MALDI-TOF/TOF-MS results of N-linked glycans from the serum glycoproteins isolated by PHA-E+L-magnetic particle conjugates showed that there was an overlap of 23 N-glycan peaks (e.g., m/z 1419.743, 1663.734, and 1743.581) between CHB, and CHC patients, 5 glycan peaks (e.g., m/z 1850.878, 1866.661, and 2037.750) were presented in virus-infected hepatitis patients compared with HV, 3 glycan peaks (1460.659, 2069.740, and 2174.772) were observed only in CHC patients. Our data provide useful information to find new biomarkers for distinguishing CHB and CHC patients based on the precision alteration of their serum glycopatterns.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparative Analysis for Glycopatterns and Complex-Type N-Glycans of Glycoprotein in Sera from Chronic Hepatitis B- and C-Infected Patients

Qin

Guo

et al. 2017

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…For example, it is not clear whether the level of HBsAg can be used to predict outcomes of ENH patients -term therapy with nucleos(t)ide analogues (NAs), or HBsAg-positive patients with normal levels of alanine aminotransferase (ALT) and low serum levels of HBV DNA (usually referred as inactive carriers of HBsAg or as carriers of inactive HBV infection)(7,13).Such individuals are not candidates for therapy unless their HBV infection becomes reactivated-then NA or other therapy is appropriate. Serum levels of HBsAg in ENH patients decrease slowly with NA therapy, so decades of continuous treatment are usually required for HBsAg clearance.…”

mentioning

confidence: 99%

Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen

Hadziyannis

2016

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

“…On the other hand, it was concluded that treatment naïve patients who underwent AVT may have even higher risk of HCC development than patients with inactive stage CHB ( 5 ). Previous data have clarified the role of HBs Ag in differentiation of CHB from IC patients; however it was mentioned not to be cost-effective ( 6 ). It was concluded that CHB patients had higher levels of HBV DNA, HBs Ag and ALT levels in comparison with IC patients ( 6 ).…”

mentioning

confidence: 99%

Letter to the Editor: Should We Really Take Anti-Viral Therapy into Account in Chronic Hepatitis B Patients with Normal Liver Function?

Khosravi

Alavian

2016

J Korean Med Sci

Self Cite

View full text Add to dashboard Cite

Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?

Cited by 10 publications

References 36 publications

Comparative Analysis for Glycopatterns and Complex-Type N-Glycans of Glycoprotein in Sera from Chronic Hepatitis B- and C-Infected Patients

Comparative Analysis for Glycopatterns and Complex-Type N-Glycans of Glycoprotein in Sera from Chronic Hepatitis B- and C-Infected Patients

Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen

Letter to the Editor: Should We Really Take Anti-Viral Therapy into Account in Chronic Hepatitis B Patients with Normal Liver Function?

Contact Info

Product

Resources

About